Dianthus Therapeutics (NASDAQ:DNTH) Earns "Outperform" Rating from Raymond James Financial

Key Points

• Raymond James Financial has restated an "outperform" rating for Dianthus Therapeutics with a new price target of $63.00, indicating a potential upside of 86.88% from the previous close.
• Recent trading saw Dianthus Therapeutics' shares increase by 6.0%, reaching $33.71, with a market cap of $1.09 billion.
• The company has reported a quarterly loss of ($0.88) EPS, missing estimates, and anticipates a -2.61 earnings per share for the fiscal year.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report)'s stock had its "outperform" rating restated by Raymond James Financial in a research note issued on Tuesday,Benzinga reports. They presently have a $63.00 target price on the stock, up from their previous target price of $56.00. Raymond James Financial's price target points to a potential upside of 86.88% from the company's previous close.

Several other equities research analysts have also commented on the company. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday. Robert W. Baird lifted their price objective on Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an "outperform" rating in a research report on Tuesday. Wedbush increased their price target on Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a research note on Thursday, August 21st. William Blair initiated coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an "outperform" rating on the stock. Finally, Guggenheim increased their price target on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday. Eight analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $60.67.

Dianthus Therapeutics Trading Up 6.0%

Shares of NASDAQ:DNTH traded up $1.91 during trading on Tuesday, hitting $33.71. 442,002 shares of the stock were exchanged, compared to its average volume of 360,275. The company has a fifty day moving average price of $21.54 and a two-hundred day moving average price of $20.09. The company has a market cap of $1.09 billion, a PE ratio of -10.30 and a beta of 1.46. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $33.43.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. Equities research analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at $27,000. US Bancorp DE increased its holdings in Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after purchasing an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Dianthus Therapeutics in the 4th quarter valued at $59,000. GAMMA Investing LLC increased its holdings in Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after purchasing an additional 3,758 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock valued at $80,000 after purchasing an additional 3,317 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.